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In order to gain a better understanding of the underlying biology of squamous cell carcinoma (SCC), we tested the
hypothesis that SCC originating from different organs may possess common molecular alterations. SCC samples (N D
361) were examined using clinical-grade targeted next-generation sequencing (NGS). The most frequent SCC tumor
types were head and neck, lung, cutaneous, gastrointestinal and gynecologic cancers. The most common gene
alterations were TP53 (64.5% of patients), PIK3CA (28.5%), CDKN2A (24.4%), SOX2 (17.7%), and CCND1 (15.8%). By
comparing NGS results of our SCC cohort to a non-SCC cohort (N D 277), we found that CDKN2A, SOX2, NOTCH1, TP53,
PIK3CA, CCND1, and FBXW7 were significantly more frequently altered, unlike KRAS, which was less frequently altered in
SCC specimens (all P < 0.05; multivariable analysis). Therefore, we identified “squamousness” gene signatures (TP53,
PIK3CA, CCND1, CDKN2A, SOX2, NOTCH 1, and FBXW7 aberrations, and absence of KRAS alterations) that were
significantly more frequent in SCC versus non-SCC histologies. A multivariable co-alteration analysis established 2 SCC
subgroups: (i) patients in whom TP53 and cyclin pathway (CDKN2A and CCND1) alterations strongly correlated but in
whom PIK3CA aberrations were less frequent; and (ii) patients with PIK3CA alterations in whom TP53 mutations were
less frequent (all P  0 .001, multivariable analysis). In conclusion, we identified a set of 8 genes altered with
significantly different frequencies when SCC and non-SCC were compared, suggesting the existence of patterns for
“squamousness.” Targeting the PI3K-AKT-mTOR and/or cyclin pathway components in SCC may be warranted.
Introduction
Squamous cell carcinomas (SCCs) occur in tissues normally
covered with squamous epithelium, and may involve many dif-
ferent organs, although 4 major sites include head and neck, cuta-
neous, esophageal, and lung SCCs.1 SCCs, other than those in
the skin, commonly metastasize,2,3 and the survival rates have
not improved in decades. A better understanding of the underly-
ing biology of SCCs is just beginning to be elucidated,4 but
would be enhanced by the characterization of their common
molecular alterations.
Defining the genetic landscape of SCCs would also facilitate
the use of targeted therapies, which have been generally lacking
for SCCs. For example, while targeted therapy employing EGFR
inhibitors is commonly used to treat lung adenocarcinomas har-
boring EGFR alterations, no effective agents have been
specifically developed for squamous cell carcinomas of the lung.
Indeed, EGFR mutations are very rare in their squamous cell
counterpart.5 Interestingly, it has been suggested that head and
neck SCCs may share patterns of molecular alterations with
SCCs of the lung.6-9 Further, esophageal and head and neck
SCCs may also share some pathogenic mechanisms.10 Examining
genetic aberrations of SCCs may shed light on additional com-
mon pathways underlying SCC tumorigenesis.
We hypothesized that squamous cell carcinomas may possess
common biologic/molecular alterations, regardless of organ of
origin. Herein, 361 tumor samples of patients with diverse squa-
mous cell carcinomas including, but not limited to, lung, head
and neck, cutaneous, gastrointestinal, and gynecologic/genitouri-
nary SCCs, were analyzed using targeted next-generation
sequencing (NGS) in order to determine if a pattern of
“squamousness” alterations could be discerned.
© Maria Schwaederle, Sheryl K Elkin, Brett N Tomson, Jennifer Levin Carter, and Razelle Kurzrock
*Correspondence to: Maria Schwaederle; Email: mschwaederle@ucsd.edu
Submitted: 04/03/2015; Revised: 05/14/2015; Accepted: 05/16/2015
http://dx.doi.org/10.1080/15384101.2015.1053669
This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/
by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The
moral rights of the named author(s) have been asserted.
www.tandfonline.com 2355Cell Cycle
Cell Cycle 14:14, 2355--2361; July 15, 2015; Published with license by Taylor & Francis Group, LLC
REPORT
Results
Genetic alterations identified in SCCs
Our squamous cell carcinomas (SCCs) cohort included 361
samples, the majority of them being SCCs of the head and neck
(N D 107, 29.6%) and lung (N D 92, 25.5%), Table 1. The
most frequent genetic alterations found were TP53 (64.5%),
PIK3CA (28.5%), CDKN2A (24.4%), SOX2 (17.7%), and
CCND1 (15.8%) (Fig. 1A). Most of the alterations were muta-
tions (61.2%) or amplifications (30.5%) (Fig. 1B). A total of
1,382 alterations were identified in 132 different genes (775 dis-
tinct alterations), Table S1. Patients had a median number of 4
(range 1–11) abnormalities identified, Figure 1C.
Specificity of the alterations
portfolio identified in SCC specimens
We next investigated if we could
identify a particular set of genes whose
alteration frequencies were different
compared to non-SCC samples. For
this purpose, we compared the altera-
tions found in 361 SCC samples (SCCs
cohort) to a separate cohort including
277 patients’ samples with diverse
malignancies, but none with SCCs
(non-SCCs cohort), that had undergone
similar next-generation sequencing test-
ing. Organ of origin breakdown was as
follows for the non-squamous tumors:
head and neck, n D 32; lung, n D 30;
cutaneous, n D 38; gynecologic/genito-
urinary (included n D 29 gynecologic
cases), n D 37; gastrointestinal, n D
117; other, n D 23. We first performed
a univariable analysis that highlighted 8
genes whose alteration frequency was
statistically different between SCC vs.
non-SCC specimens. Because there
were imbalances in the number of
patients for some tumor types (i.e.
organs of origin) between the SCC and
non-SCC cohorts (gastrointestinal, head
and neck, and lung, all P < 0.05) we
included these tumor types and the 8
genes identified in the univariable analy-
sis as variables for a multivariable model.
The results of the multivariable con-
firmed that 8 genes had statistically dif-
ferent alteration frequencies. More
specifically, 7 genes were found to be
significantly more altered in SCC speci-
mens compared to non-SCCs, as fol-
lows: CDKN2A (24% versus 8%, P D 0
.003), SOX2 (18% vs. 1%, P D 0 .001),
NOTCH1 (12% versus 1%, P D 0
.0002), TP53 (65% vs. 45%, P D 0
Table 1. Histologies breakdown of 361 squamous cell carcinomas
Squamous Cell Carcinomas (N D 361 )
Histology Number (%)
Head and neck 107 (29.6%)
Lung 92 (25.5%)
Cutaneous 36 (10.0%)
Gynecologic/Genitourinarya 40 (11.1%)
Gastrointestinal (GI)b 51 (14.1%)
Unknown origin 35 (9.7%)
TOTAL 361 (100%)
aIncluded cervical, n D 22; vagina, n D 5; vulva, n D 3; penile, n D 6; blad-
der, n D 2; and urethra, n D 2.
bIncluded esophageal, nD 21; anal, nD 21; rectal, nD 7; and gallbladder, nD 2.
Figure 1. Frequency and type of molecular alterations identified in 361 patients with diverse squa-
mous cell carcinomas. (A) Bar graph representing the alteration frequency. Only the more frequent
alterations are represented (at least 10 patients with the alteration), and some patients had multiple
alterations in the same gene. (B) Pie chart displaying the different type of alterations. Other refers to
truncation (n D 11 ), fusion (n D 3 ), rearrangement (n D 3 ), deletion (n D 2 ), and duplication (n D 1 ).
(C) Bar graph representing the number of patients by number of molecular alterations. Patients had a
median of 4 alterations, (range 1–11).
2356 Volume 14 Issue 14Cell Cycle
.004), PIK3CA (29% versus 9%, P < 0.0001), CCND1 (16% vs.
4%, P D 0 .001), and FBXW7 (7% versus 3%, P D 0 .048),
Table 2 and Figure 2. Of note, the only gene that was statistically
less frequently altered in SCC specimens was KRAS (6% in SCC
vs. 15% in non-SCC cases, P D 0 .001).
We then used the 8 genes found to be significantly differen-
tially altered in squamous cases versus non-squamous cases (more
frequent in SCC: TP53, PIK3CA, CCND1, CDKN2A, SOX2,
NOTCH 1, FBXW7; less frequent in SCC: KRAS) as a “signature”
set of altered genes (“squamousness” signature). To confirm the
specificity of this signature in SCCs, we scored all tumor samples
by allocating one point for each gene of the signature altered and
for each patient. As KRAS alterations were found less frequently in
squamous cases, it was the absence of KRAS that was given 1 point
(as opposed to all the other genes of the signature for which the
presence of the alteration gave 1 point). Since the signature com-
prised 8 genes, each patient could cumulate a maximum of 8
points. Overall, SCC cases had a median of 3 points vs. only 1 for
non-SCC specimens (P < 0.0001). The overall population (SCC
and non-SCC cases) had a median of 2 points. We found that the
Table 2. Alteration frequency differences in squamous versus non-squamous cell carcinomas (multivariable analysis)
Squamous cases (N D 361) Non-Squamous cases (N D 277) Wald statistic Odds Ratio CI 95% P-Value
Alterations
TP53 233 (65%) 125 (45%) 8.4 1.82 1.22–2.74 0.004
PIK3CA 103 (29%) 26 (9%) 20.7 3.86 2.16–6.91 <0.0001
CDKN2A 88 (24%) 23 (8%) 8.8 2.44 1.35–4.39 0.003
SOX2 64 (18%) 3 (1%) 10.8 7.94 2.31–27.3 0.001
CCND1 57 (16%) 12 (4%) 10.7 3.57 1.67–7.65 0.001
NOTCH1 43 (12%) 4 (1%) 13.9 8.38 2.74–25.6 0.0002
FBXW7 25 (7%) 7 (3%) 3.9 2.70 1.01–7.20 0.048
KRAS 21 (6%) 66 (24%) 11.8 0.33 0.18–0.62 0.001
For all the included variables, the P-values in the univariable analysis were <0.001. To account for imbalances of number of cases in certain tumor types,
lung, gastrointestinal, and head and neck histologies were also computed in the multivariable. All P-values remained significant in the multivariable analysis.
Further, a bootstrapping analysis (5,000 bootstrap samples) confirmed the results, with all P-values0 .005, except FBXW7, with PD 0 .029). Genes altered in
more than 20 SCC cases were included.
Figure 2. Significant differences in frequency of molecular alterations
between squamous vs. non-squamous cases. Only genes that were
found to be aberrant at statistically different rates (Table 2) in squa-
mous versus non-squamous cancers were included. (A) Bar graph com-
paring the alteration frequencies between squamous vs. non-
squamous cases. (B) Raw data on each patient in a “reverse array” fash-
ion. Each pink bar corresponds to an alteration in the designated gene
in one patient. Squamous cases have an over-representation of altera-
tions in all the genes included, except KRAS (whose alterations are
under-represented in SCCs). All the P-values were 0 .001, except for
FBXW7 (P D 0 .048). All detailed P-values can be found in Table 2.
Figure 3. Squamousness signature frequency: comparison by histology.
For this analysis, one point (cumulative) was given for each of the genes
where abnormalities were more prevalent in squamous tumors–TP53,
PIK3CA, CCND1, CDKN2A, SOX2, NOTCH1, and FBXW7– each time they
were present. Because KRAS aberrations were significantly less prevalent
in squamous tumors, 1 point was also assigned for the absence of KRAS.
The numbers were then added up for each case. Overall, squamous cases
had a median of 3 points versus only 1 point for non-squamous cases, P
< 0.0001. In this bar graph, we represented the percentages of patients
with 2 points (2 points was the median for the overall population
(squamous and non-squamous cases)). All the P-values comparing squa-
mous (blue bars) vs. non-squamous cases (red bars) were 0 .006. When
comparing squamous tumors of a particular histology with all other
squamous tumors (blue versus green bars), no significant differences
were seen. For details on numbers and P-values refer to Table S2.
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percentage of number of specimens with  2 points was signifi-
cantly higher in squamous cases than in non-squamous cases
(82% versus 43%, P < 0.0001). These results were also statisti-
cally significant within all primary site of origins (all P  0 .006),
Figure 3. Further, when comparing squamous tumors of a partic-
ular site of origin to all other squamous tumors, no significant dif-
ferences were discerned (Fig. 3 and Table S2). These results
demonstrate that even though the tumor specimens share the
same tissue location, their genetic characteristics were statistically
different depending on their status as a squamous tumor or not.
Co-alteration analysis
We then conducted a multivariable co-alteration analysis for
TP53, which was by far the most altered gene in SCCs (64.5%
among the SCC cases, Fig. 1A). This analysis established that
TP53 alterations strongly correlated with aberrations in the cyclin
pathway components CDKN2A and CCND1 (P < 0.0001), Fig-
ure 4A. TP53 and CDKN2A/CCND1 co-alteration was more
frequently observed in squamous cases
than in non-squamous cases (31% vs.
9%, P<0.0001), though it was also
observed in non-squamous cases (P D 0
.003, Fig. 4B). More specifically, the
co-alteration frequencies of TP53 and
CDKN2A/CCND1 were as follows:
37.4% for head and neck SCC (vs.
15.6% in non-squamous head and neck
cancers), 29.3% for SCC of the lung
(vs. 6.7 in non- squamous lung can-
cers), 23.5% for gastro-intestinal SCC
(vs. 9.4% for non-squamous gastro-
intestinal cancers), and 7.5% for gyne-
cologic/genitourinary SCC (vs. 0% of
37 cases in non-squamous gynecologic/
genitourinary cancers.
In contrast, cases with TP53 altera-
tions (versus wild-type TP53) had less
PIK3CA alterations in squamous cases (P
D 0 .001); this difference was not
observed in non-squamous specimens,
Figure 4A. In addition, we detected that
SOX2 alterations were statistically associ-
ated with PIK3CA alterations (P <
0.0001) in squamous cases (Fig. 4C),
but not in non-squamous cases
(Fig. 4D). PIK3CA and SOX2 co-altera-
tions were the most frequently observed
in lung SCC (24% vs. 3.3 in lung non-
SCC), followed by 11.8% in gastro-
intestinal SCC (vs. 0% of 117 non-squa-
mous gastro-intestinal cases), 10% in
gynecologic/genitourinary SCC (vs.
2.7% in non-squamous gynecologic/
genitourinary cancers), 9.3% in head
and neck SCC (vs. 3.1% in non-squa-
mous head and neck cancers). Of note,
none of the cutaneous cases (squamous or not) harbored PIK3CA/
SOX2 co-alterations.
Discussion
Our study examined different types of SCC specimens by tar-
geted next-generation sequencing and demonstrated that the
most commonly altered genes across squamous tumors were
TP53 (64.5%), PIK3CA (28.5%), CDKN2A (24.4%), SOX2
(17.7%), and CCND1 (15.8%), Figure 1. Furthermore, when
comparing the alterations portfolio of SCC specimens with alter-
ations found in non-SCC cases, we established that 8 genes had
alteration frequencies that were statistically different when SCCs
and non-SCC cases were compared in a multivariable analysis.
While TP53, PIK3CA, CDKN2A, CCND1, SOX2, NOTCH1
and FBXW7 were found to be significantly more frequently
altered in SCCs vs. non-SCCs, KRAS appeared to be less altered.
In a review recently published11 and focusing on head and neck
Figure 4. Significant co-alterations in patients with SCCs. Reverse array plot displaying raw data. Each
pink bar corresponds to an alteration in the designated gene in one patient (total N D 361 SCC and
N D 277 non-SCC specimens). (A) (squamous cases) and (B) (non-squamous cases) have been sorted
according to the presence of TP53 mutations. Panel A shows that within squamous tumors, TP53 is co-
altered with CDKN2A/CCND1, P < 0.0001 (P-values were also 0 .001 if CDKN2A and CCND1 were con-
sidered separately). There also was a negative association between TP53 and PIK3CA alteration,
P D 0.001. (B) shows that within non-squamous tumors, TP53 alterations were also associated with
CDKN2A/CCND1, P D 0 .003 (P-value D 0 .008 for CCND1 and P D 0 .129 for CDKN2A when considered
separately). However, the co-alteration frequency of TP53 and CDKN2A/CCND1 was significantly higher
in squamous tumors (31% vs. 9%, P < 0.0001). No association (positive or negative) was found between
TP53 and PIK3CA in non-squamous cases. (C) (squamous cases) and (D) (non-squamous cases) display
the same data as panel A and B, but sorted by the presence of PIK3CA alteration. Within squamous
tumors, PIK3CA is co-altered with SOX2 (P < 0.0001). (D) PIK3CA alterations are not significantly associ-
ated with SOX2 in non-squamous tumors.
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SCCs, the most commonly altered genes were TP53, NOTCH1,
HRAS, PIK3CA, as well as CDKN2A; additional studies focusing
on other pathologic diagnoses, such as esophageal,10 or lung can-
cer,12,13 reported alterations in genes overlapping with our find-
ings. Of note, 5.6% of our head and neck specimens carried
HRAS alterations (6/107 cases), while only one single specimen
harbored a KRAS alteration (0.9%), consistent with what has
been previously described in head and neck SCCs.7,8
More than half of the specimens carried TP53 alterations
(64.5%), making this tumor suppressor gene the most commonly
mutated gene in SCCs. TP53 is the gatekeeper of the genome
and has crucial function such as DNA repair, apoptosis, and cell
cycle arrest. TP53 alterations have been identified as early events
in the disease and have been associated with disease progression
and a poorer outcome.11 Therapies targeting TP53 loss of func-
tion are currently being explored in clinical trials, and several
studies suggest that patients harboring TP53 alterations might
respond better to angiogenesis inhibitors.14,15 Of note, a TP53
adenoviral-based treatment (rAd-p53; Gendicine) for patients
with HNSCC has recently been approved for use in China.16
Cyclin-dependent kinase inhibitor 2A (CDKN2A), located at
chromosome 9p21, is another well-known tumor suppressor
gene involved in the regulation of cell cycle progression and was
altered in 24.5% of our SCC cases. Cyclin D1 (CCND1),
another component of this pathway, was also found highly
altered in SCCs (15.8%). CCND1 interacts with CDK4/6 and
forms complexes that play a central role in the G1/S transition of
the cell cycle, acting by phosphorylating Rb.17-19 Several agents
targeting the cyclin pathway are undergoing clinical phases. Stud-
ies of one such agent, palbociclib, have produced encouraging
data in women with breast cancer20 and has been recently
approved by the FDA (Feb 2015). Given the high incidence of
cyclin pathway alterations in SCCs, testing cyclin-pathway inhib-
itors in clinical trials may be warranted in patients with SCCs.
Another highly activated pathway in SCCs appeared to be the
PI3K-Akt-mTOR axis, as reflected by the high incidence of
PIK3CA alterations. This pathway also leads to an increased trans-
lation of CCND1 and plays a crucial role in the cell cycle,21-23 as
well as migration and invasion.24 Further, alteration of this path-
way components, such as PIK3CA, may confer resistance to agents
targeting upstream constituents, such as EGFR inhibitors, as
many receptor tyrosine kinases (RTKs) activate PI3K.24 Of note, a
case series investigating the use of an mTOR inhibitor for patients
with head and neck SCCs and PTEN loss or PIK3CA mutations
showed significant tumor regression in 3 of 5 patients.25
SOX2 is a transcription factor encoded at 3q26.33, which can
act either as a suppressor or activator of gene transcription.
SOX2 has been implicated in cellular reprogramming and nor-
mal embryogenesis mechanisms,26 and may represent an impor-
tant player in tumor initiation and progression of SCCs.27,28 We
have found that 18% of our specimens harbored SOX2 amplifica-
tions (compared to only 1% in non-squamous cases), making this
gene a hallmark candidate for SCCs. Further, we found that
SOX2 and PIK3CA were highly co-altered (P < 0.0001 in multi-
variable analysis), which may be explained by their chromosomal
co-localization at 3q26.33.29
NOTCH1 is believed to play important roles in different bio-
logical processes disturbed in cancer, and NOTCH1 alterations
were identified in 12% of our SCC samples (versus 1% in non
SCCs). Murine models have highlighted the importance of
NOTCH1 in squamous epithelial differentiation, and in cutane-
ous SCC, recent sequencing efforts also suggest loss of function
mutational pattern of NOTCH1.30-32 Indeed, in our subset of
cutaneous SCCs, NOTCH1 alterations were found in 33% of
cases, vs. 10% in the other types of SCCs, (P D 0 .016 in a multi-
variable analysis, data not shown). Interestingly, in addition to
NOTCH1 alterations, FBXW7 alterations were identified in 7%
of our SCC specimens, versus 3% in non-SCC cases (P D 0 .048
in multivariable). FBXW7 forms part of the ubiquitin ligase
complex that can mediate NOTCH1 degradation; consequently,
FBXW7 mutations could also be affecting the NOTCH1 path-
way,11 although FBXW7 is also known to target other oncogenic
pathways by degrading cyclin E and c-myc.33
In the recent years, human papilloma virus (HPV) has emerged
as a primary etiology of oropharyngeal cancers,13 as well as cutane-
ous and lung SCCs.1 HPV positive–associated cancers exhibit dif-
ferent characteristics (e.g. risk factors, epidemiology) but also a
distinct clinical course. Not surprisingly, the alterations identified
in these subgroups are also different. Several studies described that
most HPV-negative samples carried TP53 as well as cyclin path-
way alterations,34-36 as opposed to HPV-positive samples which
appeared to harbor more PIK3CA alterations.35,37 Of potential
interest, another study showed that squamous-like tumors without
TP53 mutations had a higher density of PIK3CA mutations.38
There are several limitations to our study. There may have been
selection bias of the specimens, as patients/physicians may have
elected to submit tissue when there were fewer standard therapeu-
tic options left. Also, the samples came from diverse institutions
and practices. However, the fact that all the samples had under-
gone the same next-generation sequencing test by the same labora-
tory improved the homogeneity of our analysis. The size of the
test panel changed from 182 to 236 genes over the course of the
study sample. However, the markers identified as part of the squa-
mousness signature were all present in both the original and
expanded panels. The pool of samples also originated from differ-
ent tissue types, and this heterogeneity may have confounded
some of the analysis, though it also was crucial to our ability to
compare squamous molecular portfolios in different malignancies.
The HPV status of our patients was not known. In future studies,
the existence of different squamousness signatures depending on
HPV status should be investigated. Finally, a confirmatory cohort
of patients should be tested to confirm our results.
In summary, we have analyzed 361 SCC specimens and
highlighted a set of 8 genes whose alteration frequency was statis-
tically different when compared to non-SCC cases (N D 277 ).
Indeed, we observed an increased frequency of TP53, PIK3CA,
CDKN2A, CCND1, SOX2, NOTCH1, and FBXW7 alterations,
while a decreased frequency of KRAS alterations was noted. These
alterations were used to generate a “squamousness signature” that
was significantly more prevalent in SCCs across malignancies
originating in different organs compared to patients with non-
squamous tumors of the same organ of origin (Fig. 3). We also
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observed co-alteration patterns and report that TP53 mutations
associated positively with CDKN2A and CCND1 alterations and
negatively with PIK3CA in SCC specimens. Of interest, KRAS, a
frequently aberrant gene in non-squamous tumors that leads to
resistance to PI3K pathway inhibitors,39-41 was significantly less
often aberrant in SCCs. A multivariable co-alteration analysis
identified 2 SCC subtypes: (i) patients in whom TP53 and cyclin
pathway (CDKN2A and CCND1) aberrations were associated
but in whom PIK3CA anomalies were less common; and (ii)
individuals with PIK3CA abnormalities, in whom TP53 muta-
tions were less frequent (all P  0 .001, multivariable analysis).
Together, this data suggests a direction for a more precise
approach for treatment of SCCs. Targeting the PI3K-AKT-
mTOR and/or cyclin pathway components may represent valu-
able investigational avenues for clinical trials in subgroups of
patients with SCCs. Future studies should concentrate on large
datasets that include full phenotypic annotation. Importantly,
NGS provides a potentially important diagnostic test that per-
mits recognition of the abnormalities present in each patient,
hence enabling the therapeutic decision-making process.
Patients and Methods
Patients
This study included 361 SCC samples that were tested using
NGS over a 2-year period of time (from December 2011 until
November 2013). All consecutive patients for whom we had data
were included in the analysis. Patients were tested on physician
request. This cohort was compared to 277 other patient samples
(separate population) comprising individuals that had diverse can-
cers (other than SCCs) who were seen at the UC San Diego
Moores Cancer Center. This non-SCCs cohort included the same
tumor sites of origin as the SCC cohort. This study was performed
in accordance with UCSD Institutional Review Board guidelines.
Next-generation sequencing
All patients (both SCC and non-SCC cohorts) had formalin-
fixed, paraffin-embedded tumor samples that were submitted to
Foundation Medicine (FoundationOneTM, Cambridge, Massa-
chusetts, http://www.foundationone.com, which is a clinical
grade CLIA-approved next-generation sequencing test). Samples
were reviewed by a pathologist to ensure the correct diagnosis.
Next-generation sequencing data were collected and interpreted
by N-of-One, Inc.. (Lexington, MA, www.n-of-one.com). For
this study, patients’ samples were tested with a 182 or 236 gene
panel; the latter sequences the entire coding sequence of 236 can-
cer-related genes and 47 introns from 19 genes often rearranged
in cancer. The entire coding sequence of the 182 or 236 cancer-
related genes was generated with an average sequencing depth of
coverage greater than 250x (full list available at http://foundatio-
none.com/genelist1.php). This method of sequencing allows for
detection of copy number alterations, gene rearrangements, and
somatic mutations with >99% specificity and >99% sensitivity
for base substitutions at 5 mutant allele frequency and >95%
sensitivity for copy number alterations. Foundation Medicine
uses a threshold of 8 copies for gene amplification.
Statistical analysis
When appropriate, Fisher’s exact tests and binary logistic
regressions (univariable and multivariable) were performed. A
bootstrapping analysis (5,000 bootstrap samples) was performed
for internal validation of the multiple logistic regression model
results used to select the genes for the “squamousness” signature.
Whenever possible, 95% confidence intervals (95% CI) were
reported. All statistical analysis were performed by author MS
with SPSS version 22.0.
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